High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan

Taro Yamazaki, Atsushi Shibuya, Saori Ishii, Nobuyuki Miura, Akira Ohtake, Nozomu Sasaki, Ryuichiro Araki, Yatio Ota, Mitsuhiro Fujiwara, Yuji Miyajima, Kimiaki Uetake, Keigo Hamahata, Koji Kato, Kiyoshi Kawakami, Hidemi Toyoda, Naohiko Moriguchi, Masahiko Okada, Masanori Nishi, Yoshiyasu Ogata, Tomohito TakimotoShoichi Ohga, Shigeru Ohta, Shin Amemiya

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Background: A nationwide, multicenter and observational study was retrospectively conducted to evaluate the clinical utility of Cepharanthin (CEP) for pediatric patients with chronic immune thrombocytopenia (ITP). Methods: Clinical and laboratory data for 46 Japanese patients aged <16 years who were diagnosed as having chronic ITP in 14 hospitals during 2001–2011, and were treated with CEP for >12 months, were analyzed. Results: Median daily CEP dose was 1 mg/kg (range, 0.12–2 mg/kg). Median platelet count prior to CEP was 20.5 × 109/L (IQR, 8.3–53.0 × 109/L), and then significantly increased to 58.5 × 109/L (IQR, 22.8–115.0 × 109/L) and 69.0 × 109/L (IQR, 23.0–134.0 × 109/L) at 12 and 24 months of treatment, respectively. No life-threatening bleeds or moderate–severe adverse events were reported. Of 38 patients who received both corticosteroids (CS) and CEP, 17 patients (45%) were weaned from CS, and 15 patients (39%) attained the reduced dose of CS. The duration from the start of CEP to the stopping of CS was a median of 413 days (range, 49–1734 days) in patients who were weaned from CS. Conclusions: CEP alone or combined with CS was useful for the management of pediatric chronic ITPs.

元の言語英語
ページ(範囲)303-308
ページ数6
ジャーナルPediatrics International
59
発行部数3
DOI
出版物ステータス出版済み - 3 1 2017

Fingerprint

Idiopathic Thrombocytopenic Purpura
Japan
Adrenal Cortex Hormones
Pediatrics
Inosine Triphosphate
Platelet Count
Multicenter Studies
Observational Studies
cepharanthine

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

これを引用

Yamazaki, T., Shibuya, A., Ishii, S., Miura, N., Ohtake, A., Sasaki, N., ... Amemiya, S. (2017). High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. Pediatrics International, 59(3), 303-308. https://doi.org/10.1111/ped.13151

High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. / Yamazaki, Taro; Shibuya, Atsushi; Ishii, Saori; Miura, Nobuyuki; Ohtake, Akira; Sasaki, Nozomu; Araki, Ryuichiro; Ota, Yatio; Fujiwara, Mitsuhiro; Miyajima, Yuji; Uetake, Kimiaki; Hamahata, Keigo; Kato, Koji; Kawakami, Kiyoshi; Toyoda, Hidemi; Moriguchi, Naohiko; Okada, Masahiko; Nishi, Masanori; Ogata, Yoshiyasu; Takimoto, Tomohito; Ohga, Shoichi; Ohta, Shigeru; Amemiya, Shin.

:: Pediatrics International, 巻 59, 番号 3, 01.03.2017, p. 303-308.

研究成果: ジャーナルへの寄稿記事

Yamazaki, T, Shibuya, A, Ishii, S, Miura, N, Ohtake, A, Sasaki, N, Araki, R, Ota, Y, Fujiwara, M, Miyajima, Y, Uetake, K, Hamahata, K, Kato, K, Kawakami, K, Toyoda, H, Moriguchi, N, Okada, M, Nishi, M, Ogata, Y, Takimoto, T, Ohga, S, Ohta, S & Amemiya, S 2017, 'High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan', Pediatrics International, 巻. 59, 番号 3, pp. 303-308. https://doi.org/10.1111/ped.13151
Yamazaki T, Shibuya A, Ishii S, Miura N, Ohtake A, Sasaki N その他. High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. Pediatrics International. 2017 3 1;59(3):303-308. https://doi.org/10.1111/ped.13151
Yamazaki, Taro ; Shibuya, Atsushi ; Ishii, Saori ; Miura, Nobuyuki ; Ohtake, Akira ; Sasaki, Nozomu ; Araki, Ryuichiro ; Ota, Yatio ; Fujiwara, Mitsuhiro ; Miyajima, Yuji ; Uetake, Kimiaki ; Hamahata, Keigo ; Kato, Koji ; Kawakami, Kiyoshi ; Toyoda, Hidemi ; Moriguchi, Naohiko ; Okada, Masahiko ; Nishi, Masanori ; Ogata, Yoshiyasu ; Takimoto, Tomohito ; Ohga, Shoichi ; Ohta, Shigeru ; Amemiya, Shin. / High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. :: Pediatrics International. 2017 ; 巻 59, 番号 3. pp. 303-308.
@article{29780adb7e01405b9cb3f983724e3ddc,
title = "High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan",
abstract = "Background: A nationwide, multicenter and observational study was retrospectively conducted to evaluate the clinical utility of Cepharanthin (CEP) for pediatric patients with chronic immune thrombocytopenia (ITP). Methods: Clinical and laboratory data for 46 Japanese patients aged <16 years who were diagnosed as having chronic ITP in 14 hospitals during 2001–2011, and were treated with CEP for >12 months, were analyzed. Results: Median daily CEP dose was 1 mg/kg (range, 0.12–2 mg/kg). Median platelet count prior to CEP was 20.5 × 109/L (IQR, 8.3–53.0 × 109/L), and then significantly increased to 58.5 × 109/L (IQR, 22.8–115.0 × 109/L) and 69.0 × 109/L (IQR, 23.0–134.0 × 109/L) at 12 and 24 months of treatment, respectively. No life-threatening bleeds or moderate–severe adverse events were reported. Of 38 patients who received both corticosteroids (CS) and CEP, 17 patients (45{\%}) were weaned from CS, and 15 patients (39{\%}) attained the reduced dose of CS. The duration from the start of CEP to the stopping of CS was a median of 413 days (range, 49–1734 days) in patients who were weaned from CS. Conclusions: CEP alone or combined with CS was useful for the management of pediatric chronic ITPs.",
author = "Taro Yamazaki and Atsushi Shibuya and Saori Ishii and Nobuyuki Miura and Akira Ohtake and Nozomu Sasaki and Ryuichiro Araki and Yatio Ota and Mitsuhiro Fujiwara and Yuji Miyajima and Kimiaki Uetake and Keigo Hamahata and Koji Kato and Kiyoshi Kawakami and Hidemi Toyoda and Naohiko Moriguchi and Masahiko Okada and Masanori Nishi and Yoshiyasu Ogata and Tomohito Takimoto and Shoichi Ohga and Shigeru Ohta and Shin Amemiya",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/ped.13151",
language = "English",
volume = "59",
pages = "303--308",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan

AU - Yamazaki, Taro

AU - Shibuya, Atsushi

AU - Ishii, Saori

AU - Miura, Nobuyuki

AU - Ohtake, Akira

AU - Sasaki, Nozomu

AU - Araki, Ryuichiro

AU - Ota, Yatio

AU - Fujiwara, Mitsuhiro

AU - Miyajima, Yuji

AU - Uetake, Kimiaki

AU - Hamahata, Keigo

AU - Kato, Koji

AU - Kawakami, Kiyoshi

AU - Toyoda, Hidemi

AU - Moriguchi, Naohiko

AU - Okada, Masahiko

AU - Nishi, Masanori

AU - Ogata, Yoshiyasu

AU - Takimoto, Tomohito

AU - Ohga, Shoichi

AU - Ohta, Shigeru

AU - Amemiya, Shin

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: A nationwide, multicenter and observational study was retrospectively conducted to evaluate the clinical utility of Cepharanthin (CEP) for pediatric patients with chronic immune thrombocytopenia (ITP). Methods: Clinical and laboratory data for 46 Japanese patients aged <16 years who were diagnosed as having chronic ITP in 14 hospitals during 2001–2011, and were treated with CEP for >12 months, were analyzed. Results: Median daily CEP dose was 1 mg/kg (range, 0.12–2 mg/kg). Median platelet count prior to CEP was 20.5 × 109/L (IQR, 8.3–53.0 × 109/L), and then significantly increased to 58.5 × 109/L (IQR, 22.8–115.0 × 109/L) and 69.0 × 109/L (IQR, 23.0–134.0 × 109/L) at 12 and 24 months of treatment, respectively. No life-threatening bleeds or moderate–severe adverse events were reported. Of 38 patients who received both corticosteroids (CS) and CEP, 17 patients (45%) were weaned from CS, and 15 patients (39%) attained the reduced dose of CS. The duration from the start of CEP to the stopping of CS was a median of 413 days (range, 49–1734 days) in patients who were weaned from CS. Conclusions: CEP alone or combined with CS was useful for the management of pediatric chronic ITPs.

AB - Background: A nationwide, multicenter and observational study was retrospectively conducted to evaluate the clinical utility of Cepharanthin (CEP) for pediatric patients with chronic immune thrombocytopenia (ITP). Methods: Clinical and laboratory data for 46 Japanese patients aged <16 years who were diagnosed as having chronic ITP in 14 hospitals during 2001–2011, and were treated with CEP for >12 months, were analyzed. Results: Median daily CEP dose was 1 mg/kg (range, 0.12–2 mg/kg). Median platelet count prior to CEP was 20.5 × 109/L (IQR, 8.3–53.0 × 109/L), and then significantly increased to 58.5 × 109/L (IQR, 22.8–115.0 × 109/L) and 69.0 × 109/L (IQR, 23.0–134.0 × 109/L) at 12 and 24 months of treatment, respectively. No life-threatening bleeds or moderate–severe adverse events were reported. Of 38 patients who received both corticosteroids (CS) and CEP, 17 patients (45%) were weaned from CS, and 15 patients (39%) attained the reduced dose of CS. The duration from the start of CEP to the stopping of CS was a median of 413 days (range, 49–1734 days) in patients who were weaned from CS. Conclusions: CEP alone or combined with CS was useful for the management of pediatric chronic ITPs.

UR - http://www.scopus.com/inward/record.url?scp=85006340228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006340228&partnerID=8YFLogxK

U2 - 10.1111/ped.13151

DO - 10.1111/ped.13151

M3 - Article

C2 - 27596055

AN - SCOPUS:85006340228

VL - 59

SP - 303

EP - 308

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 3

ER -